Drug Trial Radar · NCT07684599
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
610
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Jul 23, 2029
Study completion Sep 18, 2031
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- ENGOT, GOG, APGOT
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see how well mocertatug rezetecan (Mo-Rez) in combination with physician's choice of immunotherapy (dostarlimab or pembrolizumab) works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared with the physician's choice of immunotherapy (dostarlimab or pembrolizumab) alone, which represents the current standard of care. The study will also assess whether the drug combination is safe and tolerated well by participants compared to standard of care and will help us better understand its impact on Health-Related Quality of Life of participants.
Conditions
- Neoplasms, Endometrial
Interventions
Mocertatug rezetecanDrug
Mocertatug rezetecan will be administered
DostarlimabDrug
Dostarlimab will be administered
PembrolizumabDrug
Pembrolizumab will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) by BICR assessmentTime frame: Up to approximately 143 weeks
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Fukushima, Japan · Recruiting
GSK Investigational Site
Hokkaido, Japan · Recruiting
GSK Investigational Site
Ibaraki, Japan · Recruiting
GSK Investigational Site
Miyagi, Japan · Recruiting
GSK Investigational Site
Numakunai, Japan · Recruiting
GSK Investigational Site
Osaka, Japan · Recruiting
GSK Investigational Site
Saitama, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Daegu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.